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Abstract
 
Ras is essential for the transition from early B cell precursors to the pro-B stage, and is consid-
ered to be involved in the signal cascade mediated by pre-B cell antigen receptors. To examine
 
the role of p21
 
ras
 
 in the late stage of B cell differentiation, we established transgenic mice (TG)
expressing a dominant-inhibitory mutant of 
 
Ha-ras
 
 (Asn-17 
 
Ha-ras
 
) in B lineage cells at high
levels after the early B cell precursor stage. Expression of p21
 
Asn-17
 
 
 
Ha-ras
 
 was associated with a
prominent reduction in the number of late pre-B cells, but had little effect on proliferation of
early pre-B cells. Inhibition of p21
 
ras
 
 activity markedly reduced the life span of pre-B cells, due,
at least in part, to downregulation of the expression of an antiapoptotic protein, Bcl-xL. Thus,
the apparent role for p21
 
ras
 
 activity in pre-B cell survival may explain the decreased numbers of
late pre-B cells in Asn-17 
 
Ha-ras
 
 TG. Consistent with this possibility, overexpression of Bcl-2
in Asn-17 
 
Ha-ras
 
 TG reversed the reduction in the number of late pre-B cells undergoing im-
munoglobulin light chain gene (
 
IgL
 
) rearrangement and progressing to immature B cells. These
results suggest that p21
 
ras
 
 mediates effector pathways responsible for pre-B cell survival, which
is essential for progression to the late pre-B and immature B stages.
Key words: B cell development • life span • immunoglobulin gene rearrangement • Bcl-xL • 
Bcl-2
 
Introduction
 
Committed B cell precursors undergo differentiation through
several critical check points into surface immunoglobulin
(sIg)
 
1
 
 positive immature B cells (for a review, see reference
1). The earliest recognizable B cell precursors were identi-
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ethidium monoazide; ERK, extracellular signal–regulated kinase; 3
 
9
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k
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9
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k
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fied in bone marrow (BM) cells expressing CD43 and a
low level of B220 (2, 3), and these cells progress to the pro-B
stage. Successful IgH gene rearrangement and transient ac-
tivation of surrogate light chain (SL) genes at the pro-B cell
stage lead to expression of the pre-B cell antigen receptor
(pre-BCR), which plays a pivotal role in allelic exclusion
and in the pre-B transition (4–8). After expansion at the
pre-B transition, pre-B cells increase the expression of the
large isoform of Bcl-x (Bcl-xL; see references 9–11) and
become competent to undergo rearrangement of the IgL
gene, probably as a consequence of the late effect mediated
by the pre-BCR (12–14).
The BCR and pre-BCR form a complex with the Ig
 
a
 
and Ig
 
b
 
 chains, which contain the immunoreceptor ty-
rosine-based activation motifs at the cytoplasmic region
(15). Upon BCR stimulation, the tyrosine kinase Syk is re-
cruited to the tyrosyl-phosphorylated immunoreceptor ty-
rosine-based activation motifs in Ig
 
a
 
 and Ig
 
b
 
 cytoplasmic
tails, followed by phosphorylation of a B cell linker protein
BLNK, also known as SH2 domain–containing leukocyte
protein of 65 kD (SLP-65), B cell adaptor containing SH2
domain (BASH), and BCA (for a review, see reference 16).
Phosphorylated BLNK interacts with several signaling mol-
ecules, resulting in regulation of membrane-associated and
soluble inositol polyphosphates and Ras–mitogen-activated
protein (MAP) kinase cascades (16). The pre-BCR may
mediate multiple effector pathways responsible for the pre-B
transition, probably through Syk, BLNK, and phosphati-
dylinositol 3-kinase (PI-3K) (17–23); however, the regula-
tory mechanism of the pre-B transition by these molecules
remains unclear.
Ras controls multiple signaling pathways by activation of
PI-3K and the guanine nucleotide exchange factors for
Ral, in addition to activation of Raf/MAP kinase kinases/
extracellular signal–regulated kinase (ERK) (24). The activ-
ity of p21
 
ras
 
 
 
in early B cell development has been previously
characterized by the expression of a dominant-inhibitory
mutant of 
 
Ha-ras
 
 (Asn-17 
 
Ha-ras
 
; reference 25) in the earli-
est B cell precursors under the control of the proximal 
 
lck
 
promoter and 
 
IgH 
 
intronic enhancer (E
 
m
 
) (26). High dose
expression of Asn-17 
 
Ha-ras
 
 caused a reduction in the
number of the earliest recognizable B cell precursors and
almost complete loss of pro-B and pre-B cells in the BM.
This maturation arrest was partially rescued by expression
of an activated form of Raf-1, suggesting a role for the
Ras-Raf-1–mediated signaling cascade in the progression
of differentiation from the earliest B cell precursors to the
pro-B stage (26). In addition, expression of constitutively
activated p21
 
ras
 
 may result in developmental progression of
the mutant pro-B cells in the absence of the H chain or re-
combination activating gene (RAG)-1, supporting the idea
that p21
 
ras
 
 could be involved in the signal cascade mediated
by the pre-BCR (27, 28). However, the role for Ras in the
progression of differentiation from the pro-B stage at phys-
iological conditions remained to be elucidated.
In this study, we established transgenic mice (TG) that
express Asn-17 
 
Ha-ras
 
 under control of the 
 
IgH
 
 promoter,
E
 
m
 
, and the 3
 
9
 
 Ig
 
k
 
 enhancer (3
 
9
 
 E
 
k
 
). In agreement with the
 
previous observation that the reporter gene linked to 3
 
9
 
 E
 
k
 
was transcriptionally activated at late-stage pro-B cell devel-
opment (29), Asn-17 
 
Ha-ras
 
 was fully expressed in B lineage
cells after the early B cell precursor stage. Through the anal-
ysis of B cell development in the BM of TG, we demon-
strated the novel finding that p21
 
ras
 
 
 
activity could be essen-
tial for pre-B cell survival, but not for proliferation of cells
during the transition from the pro-B to early pre-B stages.
 
Materials and Methods
 
Establishment of Asn-17 Ha-ras TG.
 
The plasmid containing
Asn-17 
 
Ha-ras
 
 was a gift of Dr. G.M. Cooper (Dana-Farber Can-
cer Institute, Boston, MA). The coding region of Asn-17 
 
Ha-ras
 
was amplified by PCR, and the 0.6-kb DNA fragment was sub-
cloned in the expression vector containing the promoter of the
V
 
H
 
186.2 gene (30), E
 
m
 
 (EcoRI–XbaI 0.8-kb fragments), 3
 
9
 
 E
 
k
 
(XbaI–SacI 0.8-kb fragments), SV40 intron (small t antigen), and
polyA signals. The final construct was microinjected into pronu-
clei of C57BL/6 fertilized eggs. We bred transgene-positive
founder mice with C57BL/6 mice, and established three inde-
pendent transgenic lines, designated N-17-52, N-17-75, and
N-17-95. These lines were maintained by breeding of heterozygous
TG with nontransgenic littermates in sister–brother mating. To
establish double TG, we crossed TG from N-17-95 with those
from either N-17-52 or N-17-75. To determine the genotypes of
offspring of littermates, we purified tail DNA and provided for
Southern blot analysis by using HindIII as restriction enzyme and
a 1.5-kb DNA fragment of SV40 polyA signal as a probe. In addi-
tion, the 
 
bcl-2
 
 transgene was introduced into the background of
Asn-17 
 
Ha-ras
 
 by crossing N-17-95 TG with Bcl-2 TG, which
were purchased from The Jackson Laboratory.
 
FACS
 
®
 
 Analysis.
 
To analyze the early B cell precursors, BM
cells were incubated with biotinylated anti-
 
m
 
, anti-
 
d
 
, anti-CD23
(BD PharMingen), antisyndecan (BD PharMingen), anti-NK1.1
(BD PharMingen), antierythroblasts (TER119), and anti–Gr-1 (BD
PharMingen) mAbs. After washing, we stained cells with allophy-
cocyanin (APC)-coupled B220 (B220
 
APC
 
; BD PharMingen),
FITC-conjugated anti-CD43 (CD43
 
FITC
 
; BD PharMingen), and
PE-coupled anti-CD24 (heat-stable antigen [HSA]
 
PE
 
) mAbs (BD
PharMingen). To analyze pro-B cells, we stained BM cells with
B220
 
APC
 
, CD43
 
FITC
 
, PE-coupled anti–BP-1/6C3 (BP-1
 
PE
 
; BD
PharMingen), and biotinylated anti-CD24 mAbs. To analyze
pre-B cells, we incubated BM cells with biotinylated mAbs
(anti-
 
m
 
, anti-
 
d
 
, anti-CD23, anti-NK1.1, antierythroblasts, and anti–
Gr-1), followed by staining with anti-B220
 
APC
 
, anti-CD43
 
FITC
 
,
and anti–BP-1
 
PE
 
 mAbs. After washing, cells were incubated with
Texas red–coupled UltraAvidin (avidin
 
TEX
 
; Leinco Technologies,
Inc.). To analyze immature and circulating B cells in the BM, we
stained cells with anti-B220
 
APC
 
, anti-HSA
 
PE
 
, biotinylated anti-
CD23, FITC-coupled anti-
 
m
 
 (anti-
 
m
 
FITC
 
), and anti-
 
d
 
FITC
 
 mAbs,
followed by incubation with avidin
 
TEX
 
. Cells were resuspended
in staining buffer containing propidium iodide (5 
 
m
 
g/ml) and an-
alyzed with a FACS Vantage™ (Becton Dickinson) equipped
with appropriate filters for five-color analysis in a dual argon laser
(488 nm)/dye laser (599 nm) system (30).
 
Analysis of pre-BCR Expression.
 
BM cells were stained with
ethidium monoazide (EMA; Molecular Probes) and a mixture of
anti-
 
m
 
FITC
 
, anti-
 
d
 
FITC
 
, anti-CD23
 
FITC
 
, anti-B220
 
TEX
 
, and BP-1
 
PE
 
mAbs. After washing, the cells were left for 20 min under UV
light for irreversible photolytic coupling of EMA to the cellular
DNA. Thereafter, the cells were washed with PBS and fixed with 
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2% formaldehyde for 30 min at room temperature. The cells were
then washed and permeabilized with a solution of 0.5% saponin
in PBS containing 1% BSA, 0.25 mM EDTA, and 10 mM Hepes,
together with 100 mg/ml of 2.4G2 and MOPC21, followed by
staining in combination with biotinylated mAb SL156 (31) at the
first step, and streptavidin-coupled APC at the second step.
Cell Cycle Analysis. BM cells were stained with EMA and
with B220FITC and anti-HSAPE mAbs. After washing, the cells
were left under UV light, washed, and fixed with 2% formalde-
hyde. The cells were then extensively washed and permeabilized
with 0.5% saponin, followed by incubation for 30 min with
Hoechst 33342 (1 mg/ml; Sigma-Aldrich) at room temperature.
DNA contents were analyzed with a FACS Vantage™ equipped
with the appropriate filters for four-color analysis in a dual argon
laser (488 nm)/UV laser (351/360 nm) system. Excitation of the
Hoechst 33342 was carried out by UV light with a maximum
wavelength of 351/360 nm, and fluorescence of the Hoechst
33342 was achieved by UV transmission at 424 6 22 nm.
Purification of BM B Cells. To enrich B cells, we incubated
BM cells with biotinylated mAbs (anti–Gr-1, anti–Mac-1, anti-
NK1.1, and anti-CD90). After washing, cells were incubated
with streptavidin-coated microbeads and separated on a MACS
column (Miltenyi Biotec). To purify pre-B cells and recirculating
B cells, we stained enriched B cells with anti-B220APC, anti-HS-
APE, anti-mFITC, anti-dFITC, and anti-CD23FITC mAbs. To purify
early B cell precursors, we stained enriched B cells with anti-
B220APC, anti-CD43FITC, and anti-HSAPE mAbs and with a mixture
of biotinylated mAbs (antisyndecan, anti-m, anti-d, and anti-CD23).
To purify pro-B cells, we stained BM cells with anti-B220APC,
anti-CD43FITC, biotinylated anti-HSA, and anti–BP-1PE mAbs.
After washing, cells were incubated with avidinTEX. Viable cells
were sorted under the forward and side scatter lymphocyte gate
on a FACS Vantage™. Reanalysis of sorted pre-B cells showed a
purity between 89 and 94%.
Analysis of Pre-B Cell Proliferation. To detect the uptake of
5-bromo-29-deoxyuridine (BrdU) by BM B cells, mice were in-
jected intraperitoneally with a single dose of 1 mg BrdU (Sigma-
Aldrich). After injection, pre-B cells were purified from individ-
ual animals by FACS® sorting and provided for staining with or
without FITC-conjugated anti-BrdU mAb (Becton Dickinson),
as described previously (30), or with or without mouse anti-
BrdU mAb (Oncogene Research Products), followed by staining
with affinity-purified goat anti–mouse IgG Fc fragments that
were conjugated with FITC (American Qualex). After washing,
cells were incubated with anti-B220APC mAb and propidium io-
dide. For staining controls, the same staining procedure was un-
dertaken for pre-B cells that were purified from C57BL/6 mice
and a B cell lymphoma, WEHI231, that was labeled in vitro with
or without BrdU. The samples were examined by confocal laser
microscopy (LSM410 Laser Scan microscope; Carl Zeiss, Inc.).
Cell Culture. We enriched B cells from pooled spleens of TG
and littermate controls (LM) from N-17-95 using a MACS sys-
tem. 5 3 106 enriched B cells (.90% B2201) were cultured in
the presence or absence of affinity-purified F(ab9)2 goat anti-m
antibody (Jackson ImmunoResearch Laboratories) or anti-CD40
mAb (BD PharMingen), as described previously (11). After sev-
eral time points, cells were harvested and subjected to Western
blot analysis for detection of Bcl-xL.
Western Blot Analysis. Cells were lysed in RIPA buffer for
analysis of p21ras, or in a buffer containing 1% NP-40, 137 mM
NaCl, 1 mM MgCl2, 0.1 mM CaCl2, 20 mM Tris-HCl (pH 9.0),
10% glycerol, 0.3 mg papain, 30 mg/ml pancreas extract, 2 mg/
ml chymotrypsin, 0.5 mg/ml thermolysin, 20 mg/ml trypsin for
analysis of Bcl-xL. The same amount of protein in each sample
was separated by SDS-PAGE on a 12 or 15% gel and transferred
to a polyvinylidene (PVDF) membrane (Millipore). Blots were
incubated with rat anti-Ras mAb (Y13-259; a gift from Dr. Na-
kafuku, Nara Institute of Science and Technology, Ikoma, Ja-
pan), mouse anti-Ras mAb (Ab-3; Oncogene Research Prod-
ucts), or mouse anti–Bcl-x mAb (Transduction Laboratories).
After washing, blots were incubated with anti–rat Ig or anti–
mouse Ig antibody coupled with peroxidase (Amersham Pharma-
cia Biotech). After washing, p21ras or Bcl-xL was visualized by
the ECL system (Amersham Pharmacia Biotech) as described pre-
viously (32). In addition, the blot was probed with mouse anti–
b-tubulin mAb (Sigma-Aldrich).
In Vitro MAP Kinase Assay. Resting B cells were purified
from pooled spleens of Asn-17 Ha-ras TG and age-matched wild-
type C57BL/6 mice and stimulated with F(ab9)2 goat anti–mouse
IgM polyclonal antibody (Jackson ImmunoResearch Laborato-
ries). These cells were provided for an in vitro kinase assay for
endogenous ERK activity, as described previously (32).
Semiquantitation of mRNA by Reverse Transcription PCR. Mes-
senger RNA of sorted cells was purified, and first-strand cDNA
was synthesized. Aliquots of cDNA were serially diluted fivefold
and provided for reverse transcription (RT)-PCR by using a Pre-
mix Taq (Takara Shuzo Co., Ltd.) or Super Taq Premix (Sawady
Technology). As a control, b-actin cDNA was amplified by
primers CCTAAGGCCAACCGTGAAAAG and TCT-
TCATGGTGCTAGGAGCCA.  H-ras cDNA was amplified by a
set of primers, TGACCATCCAGCTGATCCAG and TTG-
CAGCTCATGCAGCC. In some experiments, additional am-
plification was performed by using nested primers TGCCAT-
CAACAACACCAAG and GCAGCCAGGTCACACTGGT.
The reaction conditions used for each primer set were as follows:
b-actin, 948C for 1 min, 588C for 1 min, and 728C for 1.5 min,
40 cycles; H-ras and H-ras nested, 948C for 1 min, 608C for 1
min, 728C 1.5 min, 45 cycles and 25 cycles, respectively.
Semiquantitation of Rearranged Igk Gene by PCR. High mo-
lecular mass genomic DNA was extracted by the proteinase K
method from purified pre-B cells. The PCR cycle was repeated
26–32 times. PCR reactions were performed to detect rearrange-
ments of Igk as described previously (33). PCR products were
detected by Southern blot hybridization to specific radiolabeled
Jk probe (1.7-kb SphI–PstI fragment) or ethidium bromide stain-
ing. To detect bcl-6, we used the following set of primers:
mBCL-6EX5, 59-GGCTCAATAATCTCGTGAAC-39, and
mBCL-6EX6, 59-AGTGACTCTCACTGCTGCTT-39.
Results and Discussion
Establishment of TG Expressing Asn-17 Ha-ras Transgene in
B Cells. We constructed the transgene by insertion of the
dominant-inhibitory mutant of Asn-17 Ha-ras (25) in an
expression cassette consisting of the VH gene promoter
(Vp), Em, and 39 Ek (Fig. 1 A). The transgene was injected
into fertilized eggs of C57BL/6 mouse origin, and three in-
dependent transgenic lines, designated N-17-52, N-17-75,
and N-17-95, were analyzed. As shown in Fig. 1 B, RT-
PCR analysis showed the greater expression of ras tran-
scripts in pre-B (top) and pro-B cells (middle) in TG from
line N-17-95 than LM. In contrast, this transcript was un-
detectable in early B cell precursors (bottom, a) without
additional amplification by nested PCR (bottom, c). These174 Requirement of Ras for Pre-B Cell Survival
results suggested that the transgene could be fully activated
in BM B cells after the early B cell precursor stage.
Immunoblot analysis showed a remarkable expression of
p21ras in pre-B and circulating B cells in the BM of N-17-
95 TG, z10-fold above the level of LM (Fig. 1 C). Fig. 1
D shows the expression of p21ras in splenocytes in N-17-75
and N-17-95 TG, approximately fivefold above the level
of LM, and, to a lesser extent, in N-17-52 TG (top). The
level of p21ras expression was low in the thymus of TG and
LM, except for TG from N-17-75 (bottom). These results
suggest that transgenic B cells expressed p21Asn-17 Ha-ras ex-
ceeding the level of endogenous p21ras.
Fig. 1 E shows that ERK activation by IgM stimulation
was reduced in resting B cells of TG from line N-17-95 by
30–50% of the wild-type C57BL/6 B cells. Similar results
were obtained by analysis of resting B cells of TG N-17-52
and N-17-75 (data not shown), suggesting that expression
of p21Asn-17 Ha-ras may significantly inhibit endogenous p21ras
activity in B cells.
Expression of Asn-17 Ha-ras Transgene Preferentially Re-
duced the Number of Pro-B Cells and Late Pre-B Cells in the
BM. As shown in Fig. 2, we evaluated B cell develop-
ment in the BM of Asn-17 Ha-ras TG by five-color flow
cytometry (30), according to the strategy established by
Hardy and colleagues (2, 3). To analyze early B cell precur-
sors (B220dullCD431HSAdull), we excluded non-B lineage
cells, Ig1 cells, and plasma cells in B220dull/1 cells (Fig. 2 a),
and monitored CD431HSAdull cells (Fig. 2 b). To analyze
pro-B cells (B220dullCD43dullHSA1), we gated B220dull
HSA1/high BM cells that consisted of pro-B cells, pre-B
cells, and immature B cells (Fig. 2 d). Subsequently,
CD431/dullHSA1 cells were gated in a B220dullHSA1/high
population (Fig. 2 e), and BP-12 pro-B cells were analyzed
(Fig. 2 f). To analyze pre-B cells (B220dullCD43dull/2
Figure 1. (A) Schematic representation of Asn-17 Ha-ras transgene.
Asn-17 Ha-ras cDNA (black box) was inserted into the vector containing
VH186.2 gene promoter (Vp), an Em fragment (white box), and a 39 Ek
fragment (gray box). (B) Expression of ras in BM B cells of TG and LM of
N-17-95. Aliquots of cDNA, synthesized from mRNA of purified early B
cell precursors (bottom), pro-B cells (middle), and pre-B cells (top), were
serially diluted fivefold, and Ras transcripts (white arrowheads in a) were
analyzed by RT-PCR assays with b-actin used as internal control (black
arrowheads in b), or by additional amplification using Ras nested primer
(white arrowhead in c). The first dilution of all samples is 1:5. (C) Expres-
sion of p21ras protein in purified pre-B cells (a) and recirculating B cells (b)
in the BM of TG and LM of N-17-95. Shown is a representative immu-
noblot performed with 10 mg total cellular protein. p21ras was visualized
with the ECL system (arrowhead). (D) Expression of p21ras protein in
splenocytes of TG (b) and LM (a) from N-17-95 (#95), N-17-75 (#75),
or N-17-52 (#52). Shown is a representative immunoblot performed
with 100 mg total cellular protein of splenocytes (top) and thymocytes
(bottom). p21ras was visualized with the ECL system (arrowheads). (E)
Resting B cells of TG from N-17-95 and age-matched C57BL/6 mice
(WT) were stimulated with anti-IgM antibody (50 mg/ml) for 2 min. The
same amount of each extract was incubated with anti-ERK2 antibody,
and the immunoprecipitates were subjected to an in vitro kinase assay
with myelin basic protein (MBP) as a substrate. Relative radioactivities of
phosphorylated MBP from each immunoprecipitate were quantitated
with an Image Analyzer (Fuji Photo Film Co., Ltd.). The extent of activa-
tion was calculated by comparison between the radioactivity given by the
immunoprecipitates of stimulated cells and that of unstimulated cells. Bars
represent the average values of fold activation of ERK in TG and LM,
summarized from five independent experiments (filled circles).
Figure 2. Flow-cytometric analysis of B cell development in the BM of
Asn-17 Ha-ras TG and LM from N-17-95. Dead cells were detected by
uptake of propidium iodide and excluded from analysis by gating. Viable
cells were analyzed under a lymphocyte gate on forward by side light scat-
ter. BM cells stained with biotinylated mAbs (anti-m, anti-d, NK1.1, anti–
Gr-1, anti–Mac-1, antisyndecan, and TER119) in combination with avi-
dinTEX (Tex) were gated out in B220dull/1 cells (a), and CD431HSAdull cells
were analyzed (b). A histogram in c represents the relative number of early
B cell precursors in TG (bold line) and LM (thin line). To analyze pro-B
cells, HSA1CD431/dull cells (e) were gated in a B220dull/1HSAhigh/1 popu-
lation (d) and BP-12 cells were monitored as pro-B cells (f). A histogram
in f represents the relative number of pro-B cells in TG (bold line) and
LM (thin line). To analyze pre-B cells, BM cells stained with biotinylated
mAbs (anti-m, anti-d, anti-CD23, NK1.1, anti–Gr-1, TER119, and anti-
CD90)/avidinTEX (Tex) were gated out in B cells (g). Subsequently, ex-
pression of CD43 and BP-1 was analyzed (h), and the number of
CD43dull/2BP-11 and CD432BP-12 cells was estimated as BP-11 and
BP-12 pre-B cells, respectively, in TG (bold line) and LM (thin line) (i). The
horizontal bar in the histogram represents the region with BP-11 cells.175 Nagaoka et al.
HSAhigh), we excluded immature and mature B cells and
non-B lineage cells (Fig. 2 g) and monitored
B220dullCD43dull/2 cells (Fig. 2 h), which can be divided
into BP-12 and BP-11 fractions (Fig. 2 i).
TG at ages between 10 and 15 wk from N-17-95 (Fig. 2
and Fig. 3 A), N-17-75 (Fig. 3 B), and N-17-52 (Fig. 3 C)
displayed a reduction in the number of pro-B cells by 40–
50% of LM. The number of early B cell precursors was
comparable between TG and LM, consistent with the re-
sults illustrated in Fig. 1 B. Among pre-B cell subsets, TG
from N-17-95 and N-17-75 reduced the number of BP-12
cells, four- to fivefold below the level of LM, more promi-
nently than the reduction in the number of BP-11 cells
(Fig. 3, A and B). A similar phenotype was observed in
N-17-52 TG, although the reduction in pre-B cells was less
marked (Fig. 3 C). Preferential reduction in the number of
pro-B and BP-12 pre-B cells was also observed in young
N-17-95 TG (Fig. 3 D). RT-PCR analysis suggested that
transgenic BP-11 and BP-12 pre-B cells expressed Asn-17
Ha-ras transcripts at comparable levels (data not shown),
excluding the possibility that preferential reduction in the
number of BP-12 pre-B cells was due to high levels of
transgene expression in this subset.
We crossed N-17-95 TG with either N-17-52 or N-17-
75 and analyzed B cell development in the BM of the off-
spring of the littermates (Fig. 4). The reduction in the
number of B cells was dose sensitive, except for the early B
cell precursors (pre–pro-B) that almost sustained the num-
ber at comparable levels in single and double TG as well as
LM. The dose effect was more pronounced in N-17-95/
N-17-75 double TG (Fig. 4 B) than in N-17-95/N-17-52
double TG (Fig. 4 A). Although the number of BP-11 pre-B
cells was reduced in N-17-95/N-17-75 double TG, by
3-fold below that of LM, the reduction in the number of
pro-B and BP-12 pre-B cells was more prominent, 15- and
30-fold below the level in LM, respectively (Fig. 4 B).
Thus, a preferential reduction in the number of BP-12 cells
Figure 3. Preferential reduction in the number of pro-B and BP-12
pre-B cells in the BM of Asn-17 Ha-ras TG. BM cells were prepared from
individual TG and LM from N-17-95 (A), N-17-75 (B), or N-17-52 (C)
of 10–15 wk of age and N-17-95 at 5–6 wk of age (D). The number of
early B cell precursors (Pre-pro-B), pro-B, and BP-11 and BP-12 pre-B
cells was estimated by FACS®, and the number per 105 viable BM cells
was recalculated (y-axis). The results show the average number of cells in
TG (gray bars) and LM (white bars), summarized from five to eight inde-
pendent experiments. Circles represent the results for individual animals.
Figure 4. Preferential reduction in the number of pro-B and late pre-B
cells by expression of Asn-17 Ha-ras transgene at different gene dosages. A
set of offspring with the genotype of N-17-52 (b), N-17-95 (c), N-17-
52/N-17-95 (d), and nontransgenic control (a) in A, or those with the
genotype of N-17-75 (b), N-17-95 (c), N-17-75/N-17-95 (d) and non-
transgenic control (a) in B were obtained by crosses between N-17-95 and
N-17-52 (A) or N-17-95 and N-17-75 (B), respectively. BM cells were
prepared from individual animals at 12–13 wk of age and subjected to
FACS® analysis. Bars represent the average number of early B cell precur-
sors (pre-pro-B), pro-B cells (pro-B), and BP-11 and BP-12 pre-B cells
(pre-B), immature B cells (immature B), and recirculating B cells (mature
B) in the BM of TG (white bars) and LM (gray bars). Filled circles repre-
sent the number of cells in individual animals. The results were summa-
rized from three independent experiments using animals of the same age.176 Requirement of Ras for Pre-B Cell Survival
in pre-B cell subsets was a common feature in animals that
expressed the Asn-17 Ha-ras transgene at different doses.
BP-1 is expressed at the pro-B to pre-B transition,
whereas the expression is downregulated at the pre-B to
immature B transition (2, 34). We observed that 30–50% of
BP-11 pre-B cells were labeled with BrdU by a single in-
jection of the reagent, three- to fourfold above the level of
BP-12 pre-B cells (data not shown). Assuming that BP-11
and BP-12 cells could be enriched by early and late pre-B
cells, respectively, we investigated whether pre-B cells
were more susceptible at the late stage than at the early
stage to any effect caused by inhibition of p21ras activity. As
shown in Fig. 5 A, we analyzed the expression of pre-BCR
in Ig2CD232B220dull B cells of N-17-95 TG, N-17-95/
N-17-52 double TG, and nontransgenic LM by using mAb
SL156 (31), which recognizes a conformational epitope on
the m and SL chain complexes. Ig2CD232B220dull B cells
contained pre-B cells and small numbers of pro-B and the
earliest B cell precursor cells (data not shown).
As shown in Fig. 5 B, pre-BCR1 cells were detected in
the BP-11 and BP-12 subsets of the B220dullIg2CD232 B
cells. Because the pre-BCR is transiently expressed at the
late pro-B to early pre-B transition (35), we speculated that
pre-BCR1BP-12 cells would be at the late pro-B stage, in
the process of maturation to BP-11 pre-B cells. The num-
ber of pre-BCR2BP-12 cells was prominently reduced by
the expression of Asn-17 Ha-ras transgene in a dose-depen-
dent manner, whereas a reduction in the number of pre-
BCR1 and pre-BCR2 BP-11 cells was less marked. Be-
cause pre-BCR1 pre-B cells enter the S phase of cell cycle
at a high frequency (35), these results support the notion
that inhibition of p21ras activity does not have much effect
on proliferating cells at the late pro-B to the early pre-B
transition.
The BP-11 cells consisted of a minor population in im-
mature B cells at comparable levels between LM and TG
from N-17-95 or N-17-95/N-17-52 (data not shown), ex-
cluding the possibility that inhibition of p21ras caused an
abnormality in the expression of BP-1. In addition, we did
not detect any B cells with an aberrant phenotype in either
the BM or spleen of the TG within the limitations of the
FACS® analysis.
Inhibition of p21ras Activity Caused a Short Life Span of Pre-B
Cells. B cells proliferate efficiently at the transition from
pre-BCR1 pre-B to large pre-B cells (35), resulting in a
substantial expansion of cell population size (35, 36). To in-
vestigate the role of p21ras in pre-B cell proliferation, we an-
alyzed the DNA content of B220dullHSA1/high B cells in the
BM of N-17-95 TG, N-17-95/N-17-52 double TG, and
LM using flow cytometry (Fig. 6, A and B). As summarized
in Fig. 6 C, 13–30% of B220dullHSA1/high B cells entered
the S phase of cell cycle in the BM of LM, at a comparable
level to that of pre-B cells (35). Although B220dullHSA1/high
B cells in TG and LM were composed of pre-B cells, im-
mature B cells, and pro-B cells (83–86, 12–15, and 1.3–3%,
respectively), proliferating B220dullHSA1/high cells could
comprise largely pre-B cells, because immature B cells are
mostly at a resting state in TG and LM (36; data not
shown). As shown in Fig. 6 C, the number of proliferating
cells was reduced in N-17-95 TG, by 60% of LM, whereas
the reduction in the number of resting B220dullHSA1/high
cells was more significant, threefold below the level found
in LM. As shown in Fig. 6, D and E, the number of resting
B220dullHSA1/high cells was remarkably reduced in N-17-
95/N-17-52 double TG, seven- to eightfold below the
level in LM. In contrast, the number of cycling B220dull
HSA1/high cells was almost comparable between N-17-95
TG and N-17-95/N-17-52 double TG. These results raised
the possibility that the late pre-B transition, but not the
early pre-B transition, could be highly susceptible to an ef-
fect caused by the inhibition of p21ras activity.
As shown in Fig. 6 F, to investigate further the role of
p21ras in the proliferation and accumulation of pre-B cells,
we injected a single dose of BrdU into TG and LM from
N-17-95. Pre-B cells were purified from the BM of indi-
vidual animals at 2, 40, and 62 h after injection and stained
with anti-BrdU mAb, followed by examination under con-
focal microscopy (30). In agreement with the results de-
picted in Fig. 6, B and D, the number of pre-B cells incor-
porating BrdU 2 h after injection was comparable between
Figure 5. Inhibition of p21ras activity caused a preferen-
tial reduction in the number of pre-BCR2BP-12 pre-B
cells. BM cells were prepared from a set of offspring with
the genotype of N-17-95 (#95), N-17-95/N-17-52 (#95 3
#52), and nontransgenic controls (LM). These cells were
stained with EMA and with anti-B220TEX, anti–BP-1PE,
anti-IgMFITC, anti-IgDFITC, and anti-CD23FITC mAbs. Af-
ter washing, the cells were fixed with formaldehyde, per-
meabilized with saponin, and stained with biotinylated
mAb SL156, followed by staining with APC-coupled
streptavidin at the second step. The cells were then ana-
lyzed under a lymphocyte gate on forward by side light
scatter (A, b) after exclusion of EMA1 cells from analysis
by gating (A, a). B2201Ig1CD231 cells were gated out
(A, c) and B220dull cells stained with or without BP-1
were analyzed for the expression of SL156 (A, d). In B,
the results show the average number of SL1561 (pre-
BCR1) cells in BP-11 or BP-12 pre-B cells in the mice
with the genotype of #95 3 # 52 (striped bars), #95 (gray bars), and LM (white bars), summarized from two independent experiments. Circles repre-
sent the data from individual animals.177 Nagaoka et al.
TG and LM, whereas in TG the number of nonlabeled
pre-B cells was reduced approximately fourfold below that
of LM (Fig. 6 F, a). BrdU-labeled pre-B cells increased in
number in the BM of LM 40 h after injection (Fig. 6 F, b),
indicating accumulation of pre-B cells after several succes-
sive proliferations at the transition from late pro-B to early
pre-B cells (35, 36). The number of labeled cells in TG was
half that in LM 40 h after injection (Fig. 6 F, b), followed
by a remarkable reduction in number 62 h after injection,
z10-fold below the level of LM (Fig. 6 F, c), suggesting
that inhibition of p21ras activity may affect the life span of
pre-B cells. The number of labeled cells in the immature B
cells was significantly low in TG relative to LM 40 and 62 h
after injection (data not shown), excluding the possibility
that transgenic pre-B cells progress to the stage of immature
B cells within periods shorter than required for the cells in
the LM.
Expression of Bcl-xL Was Downregulated in Transgenic Pre-B
Cells. Bcl-xL plays a critical role in regulating pre-B cell
survival (9–11). To investigate whether the short life span
of transgenic pre-B cells might reflect the low levels of Bcl-
xL expression, we analyzed the expression by Western
blotting analysis in pre-B cells that were purified from the
pooled BM of TG and LM of N-17-95. Fig. 7 A shows
that pre-B cells expressed Bcl-xL, as previously reported
(11), and the level of expression was reduced in transgenic
pre-B cells, two- to threefold below the level in LM. RT-
PCR analysis showed that BP-11 and BP-12 pre-B cells
expressed bcl-xL transcripts at comparable levels in both
N-17-95 TG and LM, but the level of expression was sig-
nificantly low in TG relative to LM (data not shown).
These results support the notion that p21ras activity is asso-
ciated with pre-B cell survival, at least in part through reg-
ulation of Bcl-xL expression.
Bcl-xL expression reaches its maximum at the small pre-B
stage (10). Although the mechanism responsible for upreg-
ulation of Bcl-xL at the pre-B stage remains unknown,
pre-BCR–mediated signaling would be one of the candi-
date elements. Considering that the pre-BCR and BCR
may activate several common signaling molecules (37), in-
cluding Ras (27, 28), we set out to determine to what ex-
tent the expression of p21Asn-17 Ha-ras has an inhibitory effect
in the upregulation of Bcl-xL in transgenic B cells via BCR
stimulation. As reported previously (11), the expression of
Bcl-xL proteins was upregulated in B cells upon IgM stim-
ulation (Fig. 7 B); however, the level was reduced in trans-
genic B cells to approximately two- to threefold below that
of LM. In addition, the expression of Bcl-xL mediated by
fied from the BM of N-17-95 TG (TG) and nontransgenic LM (LM) af-
ter injection of BrdU (1 mg). Cells were mounted on a glass slide, fixed,
and stained with anti-BrdU mAb. Frequency of labeled cells was deter-
mined under confocal microscopy, and the number of labeled (gray bars)
and nonlabeled cells (white bars) was calculated based on the total number
of viable pre-B cells in BM cells for sorting. Bars represent the average
number of cells. Filled circles represent the results for individual animals at
12–15 wk of age.
Figure 6. Inhibition of p21ras activity reduced the life span of pre-B
cells. In A, BM cells were stained with anti-B220FITC and anti-HSAPE
mAbs and with EMA. After fixation and permeabilization with saponin,
cells were stained with Hoechst 33344, followed by FACS® analysis for
B220dullHSA1/high B cells (c, G3) and B2201HSAdull circulating B cells (c,
G4), as a control, under a lymphocyte gate on forward (FSC) by side
(SSC) light scatter (A, b, G2) after exclusion of EMA1 cells from analysis
(A, a, G1). In B, DNA content of pre-B (B220dullHSA1/high) cells of TG
from N-17-95 (b) and LM (a) and that of B2201HSAdull circulating B
cells in the BM of TG (d) and LM (c) is shown in each histogram. The
average number of cells at a resting state (white bars) and in the S phase of
the cell cycle (gray bars) was calculated from the results in B and plotted
in C. Circles represent the data from individual animals at 12–14 wk of
age. In D, DNA content of pre-B cells of TG with the genotype of
N-17-95 (#95, b), N-17-95/N-17-52 (#95 3 #52, c), and LM (a) is shown
in each histogram. The average number of resting and cycling pre-B cells
in LM (white bars), #95 (gray bars), and #95 3 #52 (striped bars) was
calculated from the results in D and plotted in E. Circles represent the
data from individual animals at 6–7 wk of age. (F) Pre-B cells were puri-178 Requirement of Ras for Pre-B Cell Survival
CD40 was reduced by the expression of p21Asn-17 Ha-ras (Fig.
7 B, d). These results suggest that p21ras may play a role in
Bcl-xL expression in B cells mediated by extracellular stim-
uli, which might occur at the pre-B stage.
Coexpression of Bcl-2 Restored the Number of Late Pre-B
Cells in Asn-17 Ha-ras TG. The results illustrated in Figs.
6 and 7 A are compatible with the view that reduction in
the number of late pre-B cells in Asn-17 Ha-ras TG may
reflect an abnormality in pre-B cell survival. Because Bcl-2
and Bcl-xL may inhibit cell death through a common path-
way (for a review, see reference 38), we examined whether
introduction of bcl-2 into the background of Asn-17 Ha-ras
transgene might rescue the reduction in the number of
pro-B and BP-12 pre-B cells (Fig. 6, C and D).
We observed that the number of early B cell precursors
was indistinguishable between offspring of crosses between
N-17-95 and Bcl-2 TG (data not shown). We could draw
no definite conclusion on the effect of Bcl-2 in the number
of pro-B cells in Asn-17 Ha-ras TG. Bcl-2 TG and Bcl-2/
N-17-95 double TG prominently expanded Ig1 B cells
with the phenotype HSA1B220dullCD43dull in the BM
(data not shown), which caused difficulty in the estimation
of pro-B cells, defined as HSA1B220dullCD43dullBP-12
cells (see Fig. 2 B). Although the nature of Ig1HSA1
B220dullCD43dull cells remains unknown at present, these
cells were barely detectable in the BM of N-17-95 TG and
LM (data not shown).
As depicted in Fig. 7 C and summarized in Fig. 7 D, the
number of BP-12 pre-B and immature B cells was compa-
rable between Bcl-2 TG (Fig. 7, C, d and h, and D, d) and
LM (Fig. 7, C, a and e, and D, a), as reported previously
(39). The number of BP-12 pre-B cells was significantly
reduced in N-17-95 TG (Fig. 7, C and D, b), whereas co-
expression of Bcl-2 restored the number from 13 to 55% of
that in LM, on average (Fig. 7, C and D, c). The number
of pre-BCR1 cells in BP-11 and BP-12 pre-B cells was al-
most comparable between Bcl-2/N-17-95 double TG and
N-17-95 TG (data not shown), supporting the notion that
coexpression of Bcl-2 did not affect the accumulation of
Figure 7. (A) Expression of Bcl-xL protein in pre-B cells. Pre-B cells
were purified from the pooled BM cells of TG and LM from N-17-95.
The cell lysate at 10 mg total protein was separated by SDS-PAGE on a
12% gel, transferred to a PVDF membrane, and visualized by anti–Bcl-x
antibody in the ECL system (top). The same blot was probed with anti–
b-tubulin mAb (bottom). Shown is a representative result from three in-
dependent experiments. (B) Expression of Bcl-xL protein in splenic B cells
upon IgM and CD40 stimulation. B cells of TG and LM from N-17-95
were cultured in the absence (a) or presence of anti-IgM antibody (60 mg/
ml in b; 20 mg/ml in c), or anti-CD40 mAb (3 mg/ml, d). After 10 h of
cultivation, cell lysates were provided for Western blot analysis for detec-
tion of Bcl-xL (arrowhead). H and L represent the IgH and IgL chains of
cultured B cells, respectively. Shown is a representative result from three
independent experiments. (C) Coexpression of Bcl-2 restored the number
of BP-12 pre-B and immature B cells in N-17-95 TG. BM cells were pre-
pared from individual offspring with the genotype of N-17-95/Bcl-2 dou-
ble TG (c and g), N-17-95 TG (b and f), Bcl-2 TG (d and h), and non-
transgenic control (a and e). Shown is a representative result of dot blot
analysis for BP-11 and BP-12 pre-B cells (a–d) and immature B cells (e–h).
(D) The number of BP-11 and BP-12 pre-B and immature B cells in LM
(a), N-17-95 TG (b), N-17-95/Bcl-2 double TG (c), and Bcl-2 TG (d).
Bars represent the average number of cells, summarized from four inde-
pendent experiments using animals at the same age between 12 and 15 wk.
Circles represent the number of cells in individual animals.
Figure 8. Relative frequency of Vk to Jk recombination in pre-B cells
of TG expressing Asn-17 Ha-ras and bcl-2 transgenes. Genomic DNA was
prepared from pre-B cells (pre-B) and immature B cells (immature B) that
were purified from the pooled BM of N-17-95 TG (#95), Bcl-2 TG
(Bcl-2), N-17-95/Bcl-2 double TG (#95 3 Bcl-2), and nontransgenic
LM (LM). Endogenous Vk–Jk regions were amplified by PCR with 26
(a), 28 (b), 30 (c), and 32 (d) cycles. DNA was separated by agarose gel
electrophoresis, and rearrangements were detected by Southern hybrid-
ization with the Jk region DNA as a probe. Similar results were obtained
in three independent experiments. For normalization of the results, bcl-6
was amplified by PCR with 28 cycles (e).179 Nagaoka et al.
pre-B cells at the early stage. The number of immature B
cells in Bcl-2/N-17-95 double TG (Fig. 7, C, g, and D, c)
was approximately twofold above the level in N-17-95 TG
(Fig. 7, C, f, and D, b); this effect was statistically significant
(P , 0.05). Taken together, these results suggest the possi-
bility that overexpression of Bcl-2 in N-17-95 TG may al-
leviate the reduction in the number of pre-B cells capable
of progression to immature B cells.
Maximal induction of IgL rearrangement occurs at the
late pre-B cell stage (14). The IgL rearrangement is pre-
ceded by an activation of the chromatin structure in the IgL
locus sufficient for substrate accessibility, which is probably
mediated by signaling through the pre-BCR (12–14). To
delineate the maturation stage of pre-B cells in Bcl-2/N-
17-95 double TG, we analyzed genomic DNA samples
from purified pre-B cells by a semiquantitative PCR to
measure the relative level of Igk recombination events. As
depicted in Fig. 8, there was no large difference in the rela-
tive level of Vk joining, involving Jk1, Jk2, and Jk4, in
pre-B cells that were purified from the BM of N-17-95
TG, Bcl-2 TG, Bcl-2/N-17-95 double TG, and LM. Al-
though semiquantitation of rearranged Igk gene by PCR
does not appear to be very sensitive, these results seem
compatible with the notion that expression of Asn-17
Ha-ras in pre-B cells could not much affect the process of
IgL rearrangement, and that an overexpression of Bcl-2 in
N-17-95 TG restored pre-B cells undergoing IgL rear-
rangement to a considerable extent. In this regard, how-
ever, it has been previously observed that introduction of
the activated form of Ha-ras into H chain–deficient mice
resulted in an accumulation of peripheral B cells that dis-
played rearrangement of the Igk locus (28). These results,
taken together, seem compatible with the idea that p21ras
mediates progression of B cell differentiation to a stage that
is accessible to the machinery for IgL rearrangement, al-
though the activity of p21ras is redundant in function with
that of other signaling molecules at the pre-B transition.
Therefore, further analysis is needed to clarify this issue.
These studies demonstrate that p21ras is essential for the
late pre-B transition and support a role for p21ras in pro-B
cell development (26). Thus, p21ras could be involved in
signaling cascades that control B cell differentiation at dif-
ferent critical points in the BM, whereas it might not be es-
sential for proliferation of cells at the pro-B to pre-B transi-
tion. Ras controls multiple signaling pathways (24), and
activation of Raf-1 may have an important role in early B
cell development in the BM (26); however, Ras-mediated
signaling cascades responsible for the late pre-B transition
remain to be specified. Mice disrupted with the p85a sub-
unit of PI-3K displayed B cell deficiency, characteristics of
decreased numbers of pre-B cells, and increased numbers of
apoptotic cells in cultured B cells (19, 20). Because PI-3K
is a direct effector of active Ras (40), the similar B cell def-
icit in the p85a2/2 mice and Asn-17 Ha-ras TG led us to
speculate that inhibition of PI-3K activation could be a
component of the late pre-B deficiency imposed by inhibi-
tion of p21ras activity.
These studies suggest that p21ras activity could be associ-
ated with pre-B cell survival, at least in part through regula-
tion of Bcl-xL expression. Expression of constitutively ac-
tive Ha-ras does not cause upregulation of bcl-x transcript in
RAG-1–deficient B lineage cells (27), suggesting that
p21Ha-ras may not transduce the signal for direct activation of
bcl-x at the pro-B stage. Therefore, we speculate that p21ras
may modulate the expression of bcl-x in concert with other
signaling molecules. Consistent with p21ras activity for pre-B
cell survival, overexpression of the antiapoptotic protein
Bcl-2 alleviated the reduction in the number of late pre-B
cells in Asn-17 Ha-ras transgenic animals, but it did not re-
store the number of cells to the normal level. Considering
that cell survival is regulated by the Bcl-2 member of pro-
teins that consists of anti- and proapoptotic members (for
reviews, see references 38 and 41), the results might imply
that p21ras provides multiple effector pathways for pre-B
cell survival, in addition to regulation of antiapoptotic ac-
tivity. In this context, it has previously been suggested that
p21ras activates Akt/protein kinase B (PKB) kinase via PI-
3K and ERK via Raf-1, which control the activity of
proapoptotic effects in different types of cells in vitro (for a
review, see reference 42). Antiapoptotic molecules may
function by inhibiting the process of caspase activation,
whereas proapoptotic proteins may independently regulate
a common apoptotic pathway or function by heterodimer-
ization with antiapoptotic proteins (38, 41). Therefore, it is
conceivable that exogenous Bcl-2 activity in Asn-17 Ha-ras
TG would be overridden by proapoptotic activity, which
could be downregulated by p21ras in pre-B cells in a normal
state. Whether p21ras regulates pre-B cell survival through
multiple effector pathways remains to be elucidated.
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